Literature DB >> 11566185

PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.

B Degryse1, C F Sier, M Resnati, M Conese, F Blasi.   

Abstract

PAI-1 (plasminogen activator inhibitor-1) binds the urokinase-type plasminogen activator (uPA) and causes its degradation via its receptor uPAR and low-density lipoprotein receptor-related protein (LRP). While both uPA and PAI-1 are chemoattractants, we find that a preformed uPA-PAI-1 complex has no chemotactic activity and that PAI-1 inhibits uPA-induced chemotaxis. The inhibitory effect of PAI-1 on uPA-dependent chemotaxis is reversed when uPAR internalization is inhibited by the 39 kDa receptor-associated protein or by anti-LRP antibodies. Under the same conditions, the uPA-PAI-1 complex is turned into a chemoattractant causing cytoskeleton reorganization and extracellular-regulated kinase/mitogen-activated protein kinases activation. Thus, uPAR internalization by PAI-1 regulates cell migration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566185     DOI: 10.1016/s0014-5793(01)02797-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  TGF-β-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche.

Authors:  Takashi Yahata; Abd Aziz Ibrahim; Yukari Muguruma; Mesut Eren; Alexander M Shaffer; Nobuo Watanabe; Satoko Kaneko; Tetsuo Nakabayashi; Takashi Dan; Noriaki Hirayama; Douglas E Vaughan; Toshio Miyata; Kiyoshi Ando
Journal:  Blood       Date:  2017-08-18       Impact factor: 22.113

2.  Antiangiogenic activity of rPAI-1(23) promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism.

Authors:  Jessica Mollmark; Saranya Ravi; Baiming Sun; Samantha Shipman; Maarten Buitendijk; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Circ Res       Date:  2011-05-05       Impact factor: 17.367

Review 3.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

4.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

Review 5.  Exosite determinants of serpin specificity.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

6.  Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity.

Authors:  Hyejin Jeon; Jong-Heon Kim; Jae-Hong Kim; Won-Ha Lee; Myung-Shik Lee; Kyoungho Suk
Journal:  J Neuroinflammation       Date:  2012-06-29       Impact factor: 8.322

7.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

Authors:  Ralf-Peter Czekay; Kathleen Aertgeerts; Scott A Curriden; David J Loskutoff
Journal:  J Cell Biol       Date:  2003-03-03       Impact factor: 10.539

8.  Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.

Authors:  Virginie Bondu; Ron Schrader; Mary Ann Gawinowicz; Paul McGuire; Daniel A Lawrence; Brian Hjelle; Tione Buranda
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

Review 9.  Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.

Authors:  Yao Ye; Aurelia Vattai; Xi Zhang; Junyan Zhu; Christian J Thaler; Sven Mahner; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

Review 10.  Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.

Authors:  V M Baart; R D Houvast; L F de Geus-Oei; P H A Quax; P J K Kuppen; A L Vahrmeijer; C F M Sier
Journal:  EJNMMI Res       Date:  2020-07-28       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.